Cancer-associated fibroblast-derived PAI-1 promotes lymphatic metastasis via the induction of EndoMT in lymphatic endothelial cells.
Cancer-associated fibroblast
Cervical squamous cell carcinoma
Endothelial-mesenchymal transition
Lymphatic metastasis
PAI-1
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
06 Jul 2023
06 Jul 2023
Historique:
received:
16
01
2023
accepted:
18
05
2023
medline:
10
7
2023
pubmed:
7
7
2023
entrez:
6
7
2023
Statut:
epublish
Résumé
Endothelial-mesenchymal transition (EndoMT) is an emerging adaptive process that modulates lymphatic endothelial function to drive aberrant lymphatic vascularization in the tumour microenvironment (TME); however, the molecular determinants that govern the functional role of EndoMT remain unclear. Here, we show that cancer-associated fibroblast (CAF)-derived PAI-1 promoted the EndoMT of lymphatic endothelial cells (LECs) in cervical squamous cell carcinoma (CSCC). Immunofluorescent staining of α-SMA, LYVE-1 and DAPI were examined in primary tumour samples obtained from 57 CSCC patients. Assessment of cytokines secreted by CAFs and normal fibroblasts (NFs) was performed using human cytokine antibody arrays. The phenotype of EndoMT in lymphatic endothelial cells (LECs), gene expression levels, protein secretion and activity of signaling pathways were measured by real-time RT-PCR, ELISA or western blotting. The function of lymphatic endothelial monolayers was examined by transwell, tube formation assay, transendothelial migration assay in vitro. Lymphatic metastasis was measured using popliteal lymph node metastasis model. Furthermore, association between PAI-1 expression and EndoMT in CSCC was analyzed by immunohistochemistry. The Cancer Genome Atlas (TCGA) databases was used to assess the association of PAI-1 with survival rate in CSCC. CAF-derived PAI-1 promoted the EndoMT of LECs in CSCC. LECs undergoing EndoMT could initiate tumour neolymphangiogenesis that facilitated cancer cell intravasation/extravasation, which in turn promoted lymphatic metastasis in CSCC. Mechanistically, PAI-1 activated the AKT/ERK1/2 pathways by directly interacting with low-density lipoprotein receptor-related protein (LRP1), thereby leading to elevated EndoMT activity in LECs. Blockade of PAI-1 or inhibition of LRP1/AKT/ERK1/2 abrogated EndoMT and consequently attenuated CAF-induced tumour neolymphangiogenesis. Furthermore, clinical data revealed that increased PAI-1 levels positively correlated with EndoMT activity and poor prognosis in CSCC patients. Our data indicate that CAF-derived PAI-1 acts as an important neolymphangiogenesis-initiating molecular during CSCC progression through modulating the EndoMT of LECs, resulting in promotion of metastasis ability in primary site. PAI-1 could serve as an effective prognostic biomarker and therapeutic target for CSCC metastasis.
Sections du résumé
BACKGROUND
BACKGROUND
Endothelial-mesenchymal transition (EndoMT) is an emerging adaptive process that modulates lymphatic endothelial function to drive aberrant lymphatic vascularization in the tumour microenvironment (TME); however, the molecular determinants that govern the functional role of EndoMT remain unclear. Here, we show that cancer-associated fibroblast (CAF)-derived PAI-1 promoted the EndoMT of lymphatic endothelial cells (LECs) in cervical squamous cell carcinoma (CSCC).
METHODS
METHODS
Immunofluorescent staining of α-SMA, LYVE-1 and DAPI were examined in primary tumour samples obtained from 57 CSCC patients. Assessment of cytokines secreted by CAFs and normal fibroblasts (NFs) was performed using human cytokine antibody arrays. The phenotype of EndoMT in lymphatic endothelial cells (LECs), gene expression levels, protein secretion and activity of signaling pathways were measured by real-time RT-PCR, ELISA or western blotting. The function of lymphatic endothelial monolayers was examined by transwell, tube formation assay, transendothelial migration assay in vitro. Lymphatic metastasis was measured using popliteal lymph node metastasis model. Furthermore, association between PAI-1 expression and EndoMT in CSCC was analyzed by immunohistochemistry. The Cancer Genome Atlas (TCGA) databases was used to assess the association of PAI-1 with survival rate in CSCC.
RESULTS
RESULTS
CAF-derived PAI-1 promoted the EndoMT of LECs in CSCC. LECs undergoing EndoMT could initiate tumour neolymphangiogenesis that facilitated cancer cell intravasation/extravasation, which in turn promoted lymphatic metastasis in CSCC. Mechanistically, PAI-1 activated the AKT/ERK1/2 pathways by directly interacting with low-density lipoprotein receptor-related protein (LRP1), thereby leading to elevated EndoMT activity in LECs. Blockade of PAI-1 or inhibition of LRP1/AKT/ERK1/2 abrogated EndoMT and consequently attenuated CAF-induced tumour neolymphangiogenesis. Furthermore, clinical data revealed that increased PAI-1 levels positively correlated with EndoMT activity and poor prognosis in CSCC patients.
CONCLUSION
CONCLUSIONS
Our data indicate that CAF-derived PAI-1 acts as an important neolymphangiogenesis-initiating molecular during CSCC progression through modulating the EndoMT of LECs, resulting in promotion of metastasis ability in primary site. PAI-1 could serve as an effective prognostic biomarker and therapeutic target for CSCC metastasis.
Identifiants
pubmed: 37415190
doi: 10.1186/s13046-023-02714-0
pii: 10.1186/s13046-023-02714-0
pmc: PMC10324144
doi:
Substances chimiques
Plasminogen Activator Inhibitor 1
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
SERPINE1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
160Subventions
Organisme : National Natural Science Foundation of China
ID : 81971341
Organisme : National Natural Science Foundation of China
ID : 82102685
Organisme : National Natural Science Foundation of China
ID : 82173227
Organisme : Science and Technology Program of Guangzhou
ID : 202102020936
Organisme : Science and Technology Program of Guangzhou
ID : 202102021057
Organisme : Guangzhou Science and Technology Program key projects
ID : 202102010223
Organisme : Guangdong Basic and Applied Basic Research Foundation
ID : 2019A1515010872
Organisme : Guangdong Basic and Applied Basic Research Foundation-the Regional Joint
ID : 2019A1515110046
Informations de copyright
© 2023. The Author(s).
Références
Theranostics. 2019 Sep 23;9(24):7168-7183
pubmed: 31695760
Cancer Metastasis Rev. 2018 Sep;37(2-3):369-384
pubmed: 29858743
Front Cell Dev Biol. 2020 Aug 14;8:747
pubmed: 32923440
Mol Oncol. 2021 Jan;15(1):210-227
pubmed: 33124726
Nat Rev Cancer. 2014 Mar;14(3):159-72
pubmed: 24561443
Am J Physiol Heart Circ Physiol. 2016 May 1;310(9):H1055-63
pubmed: 26993222
J Clin Invest. 2016 May 2;126(5):1801-14
pubmed: 27043280
Nat Rev Gastroenterol Hepatol. 2019 May;16(5):282-295
pubmed: 30778141
J Biol Chem. 2010 May 7;285(19):14308-17
pubmed: 20220145
Cancer Lett. 2015 Jun 1;361(2):155-63
pubmed: 25700776
J Cell Mol Med. 2019 Apr;23(4):2984-2994
pubmed: 30734495
Angiogenesis. 2018 Aug;21(3):635-652
pubmed: 29675549
Cancer Res. 2015 Jan 15;75(2):284-95
pubmed: 25488750
Front Cardiovasc Med. 2020 Dec 22;7:622473
pubmed: 33415130
Cancer Res. 2014 Oct 1;74(19):5597-607
pubmed: 25142796
Nat Med. 1998 Aug;4(8):923-8
pubmed: 9701244
Mol Oncol. 2019 Aug;13(8):1706-1724
pubmed: 31094056
Front Immunol. 2019 Apr 09;10:720
pubmed: 31024552
Cancer Res. 2015 Aug 1;75(15):2969-74
pubmed: 26180080
Oncogene. 2017 Mar;36(11):1503-1515
pubmed: 27593938
Lab Invest. 2021 Mar;101(3):353-368
pubmed: 33311557
Curr Opin Immunol. 2018 Aug;53:7-12
pubmed: 29605736
Oncogene. 2021 Feb;40(8):1476-1489
pubmed: 33452453
J Transl Med. 2022 Jul 21;20(1):322
pubmed: 35864535
Cell Rep. 2020 Oct 13;33(2):108253
pubmed: 33053339
Science. 2020 Jul 10;369(6500):
pubmed: 32646971
Ups J Med Sci. 2015;120(3):135-43
pubmed: 26220421
J Clin Invest. 2001 Sep;108(6):779-84
pubmed: 11560943
Cell Death Dis. 2017 Dec 14;8(12):3220
pubmed: 29242498
Cell Death Dis. 2018 Jul 9;9(7):759
pubmed: 29988148
Cell Metab. 2019 Nov 5;30(5):917-936.e10
pubmed: 31447322